How to buy Biogen (BIIB) shares in the UK

Learn how to easily invest in Biogen shares.

Biogen Inc
NASDAQ: BIIB - USD
DRUG MANUFACTURERS-GENERAL
$271.94
+ $2.00 ( + 0.74%)

Biogen Inc (BIIB) is a leading drug manufacturers-general business based in the US. It opened the day at $300.85 after a previous close of $299.69. During the day the price has varied from a low of $296.56 to a high of $300.85. The latest price was $300.19 (25 minute delay). Biogen is listed on the NASDAQ and employs 9,100 staff. All prices are listed in US Dollars.

How to buy shares in Biogen

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BIIB in this case.
  5. Research Biogen shares. The platform should provide the latest information available.
  6. Buy your Biogen shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Biogen's share price?

Since the stock market crash that started in February 2020, Biogen's share price has had significant negative movement.

Its last market close was $269.94, which is 19.83% down on its pre-crash value of $336.71 and 2.93% up on the lowest point reached during the March 2020 crash when the shares fell as low as $262.25.

If you had bought $1,000 worth of Biogen shares at the start of February 2020, those shares would have been worth $987.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $990.68.

Biogen share price (NASDAQ:BIIB)

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

Information last updated 2021-09-17.
Open$300.85
High$300.85
Low$296.56
Close$300.19
Previous close$299.69
Change$0.5
Change %0.1668%
Volume1,680,045
Information last updated 2021-10-23.
52-week range$223.25 - $427.5
50-day moving average$289.9211
200-day moving average$311.8058
Wall St. target price$366.93
PE ratio21.1772
Dividend yieldN/A (0%)
Earnings per share (TTM)$12.504
Promoted
eToro Free Stocks

Invest in Biogen shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 5x Biogen shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Freetrade logo £0 No minimum £4.91
£1,095.65 total
Capital at risk
eToro Free Stocks logo £0 $50 £5.45
£1,096.19 total
Capital at risk
Fineco logo £0 No minimum £10.91
£1,101.65 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.53
£1,092.27 total
Capital at risk
Stake logo £0 £50 £5.47
£1,096.21 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £22.87
£1,113.61 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £24.37
£1,115.11 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £23.15
£1,113.89 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Biogen under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Biogen shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Biogen's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.

PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Biogen's PEG ratio in relation to those of similar companies.

EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.3 billion (£2.4 billion).

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Financials

Revenue TTM $11.7 billion
Operating margin TTM 24.03%
Gross profit TTM $11.6 billion
Return on assets TTM 7.03%
Return on equity TTM 22.14%
Profit margin 16.4%
Book value $72.112
Market capitalisation $38.9 billion

TTM: trailing 12 months

How to short and sell Biogen shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BIIB.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 2.5 million Biogen shares held short by investors – that's known as the "short interest". This figure is 1.8% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.

Short interest ratio (SIR)

Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.1 million). Biogen's SIR currently stands at 2.35. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2350 shares are currently held short.

To gain some more context, you can compare Biogen's short interest ratio against those of similar companies.

However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.0188% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.

Find out more about how you can short Biogen stock.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.

Total ESG risk score

Biogen's total ESG risk: 22.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Biogen's total ESG risk score against those of similar companies.

Environmental score

Biogen's environmental score: 1.02/100

Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Biogen's social score: 13.48/100

Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Biogen's governance score: 7.45/100

Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Biogen's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Biogen Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.95
Total ESG percentile 33.82
Environmental score 1.02
Environmental score percentile 2
Social score 13.48
Social score percentile 2
Governance score 7.45
Governance score percentile 2
Level of controversy 2

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

You may also wish to consider:

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $223.25 up to $427.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.4704. This would suggest that Biogen's shares are less volatile than average (for this exchange).

To put Biogen's beta into context you can compare it against those of similar companies.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Shares similar to Biogen

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site